Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response

Bradley A Maron^{1

2}

Affiliations

Editorial

Bradley A Maron. Am J Respir Crit Care Med. 2025 Jun.

. 2025 Jun;211(6):906-907.

doi: 10.1164/rccm.202503-0539ED.

Bradley A Maron^{1

2}

No abstract available

Comment on

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).
Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M. Montani D, et al. Am J Respir Crit Care Med. 2025 Jun;211(6):1028-1037. doi: 10.1164/rccm.202409-1698OC. Am J Respir Crit Care Med. 2025. PMID: 40035659 Clinical Trial.

1. Johnson S, Sommer N, Cox-Flaherty K, Weissmann N, Ventetuolo CE, Maron BA. et al. Pulmonary hypertension: a contemporary review. Am J Respir Crit Care Med . 2023;208:528–548. - PMC - PubMed
1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation . 2010;122:156–163. - PubMed
1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB. et al. Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med . 1996;334:296–301. - PubMed
1. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ . 2018;360:j5492. - PMC - PubMed
1. Austin ED, Aldred MA, Alotaibi M, Gräf S, Nichols WC, Trembath RC. et al. Genetics and precision genomics approaches to pulmonary hypertension. Eur Respir J . 2024;64:2401370. - PMC - PubMed